Attached files

file filename
EX-99.1 - Protagenic Therapeutics, Inc.\newex99-1.htm
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported): December 9, 2010


ATRINSIC, INC.
 (Exact name of registrant as specified in its charter)
 
Delaware
001-12555
06-1390025
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

469 7th Avenue, 10th Floor, New York, NY 10018
(Address of Principal Executive Offices/Zip Code)

(212) 716-1977
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
þ
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

Other Events
 
On December 9, 2010, Mr. Thomas Plotts, Chief Financial Officer, of Atrinsic, Inc. made a presentation at the LD Micro Investment Conference in Beverly Hills, California in which certain financial and non financial  information was discussed. The presentation materials are attached as Exhibit 99.1 hereto, and are incorporated herein by reference.
 
In addition to historic information, this report, including the exhibit, contains forward-looking statements regarding events, performance and financial trends. Various factors could affect future results and could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Some of those factors are identified in the exhibit, and in our periodic reports filed with the Securities and Exchange Commission.
 
Additional Information About the Proposed Transaction and Where You Can Find It
 
This document may be deemed to be solicitation material in respect of the proposed acquisition by Atrinsic of all of the assets of Brilliant Digital Entertainment, Inc. (“BDE”) that relate to BDE’s Kazaa subscription based music service business. In connection with the proposed transaction, a proxy statement will be filed by Atrinsic with the SEC. STOCKHOLDERS OF ATRINSIC ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ASSET ACQUISITION. The final proxy statement will be mailed to stockholders of Atrinsic. Investors and security holders will be able to obtain the documents free of charge at the SEC’s website, www.sec.gov, or from Atrinsic, at Atrinsic, Inc., Attention: Investor Relations, 469 7th Avenue, 10th Floor, New York, NY, 10018.
 
Atrinsic and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies in respect of the transaction.  Information regarding the identity of the persons who may, under SEC rules, be deemed to be “participants” in the solicitation of proxies, and a description of their direct and indirect interests in the solicitation, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC when they become available.

Item 9.01.
Financial Statements and Exhibits
 
 
(d)
Exhibits.
 
The following exhibit is filed herewith:
 
 
Exhibit
Number  
Description
 
99.1
Presentation materials.
 
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
    Atrinsic, Inc.
     
Date: December 9, 2010
By:  
/s/ Thomas Plotts
     
     Thomas Plotts
Chief Financial Officer
 
 
 

 
 
Exhibit
Number  
Description
   
99.1
Presentation materials.